Acumen Pharmaceuticals Inc. Co-Founders Link Alzheimer's Cause to Insulin Resistance

Published: Oct 22, 2007

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acumen Pharmaceuticals, a leading pre-clinical biotech company in Alzheimer’s therapeutics, announced the publication of a groundbreaking study demonstrating that ADDLs (amyloid ß-derived diffusible ligands) block key insulin signaling pathways in the brain. The study, co-authored by Acumen founder and chief science officer Dr. Grant Krafft, former Acumen scientist Dr. Wei-Qin Zhao, and scientists in the laboratory of Acumen co-founder Dr. William Klein, appeared in the recent issue of the Federation of American Societies for Experimental Biology (FASEB) Journal.

Back to news